Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423901 | 0.90 | GPR35 (0.41) | SLC6A9NOTUMGPR35CES2AKR1C3 | |
| SCHEMBL31258876 | 0.85 | SLC6A9 (0.48) | SLC6A9SCN8ASCN10AAKR1C3AKR1C2 | |
| SCHEMBL420816 | 0.85 | SLC6A9 (0.48) | SLC6A9SCN8ASCN10AAKR1C3AKR1C2 | |
| SCHEMBL18394005 | 0.82 | CES2 (0.47) | NOTUMGPR35CES2 | |
| SCHEMBL842185 | 0.80 | SLC6A9 (0.47) | SLC6A9 | |
| SCHEMBL3023015 | 0.80 | CES2 (0.42) | SCN8ASCN10ANOTUMGPR35CES2 | |
| SCHEMBL421721 | 0.78 | CA12 (0.52) | SLC6A9NOTUMCES2AKR1C3AKR1C2 | |
| SCHEMBL15901970 | 0.76 | CES2 (0.42) | SCN8ASCN10ANOTUMGPR35CES2 | |
| SCHEMBL14817465 | 0.76 | NOTUM (0.51) | SLC6A9NOTUMGPR35CES2AKR1C3 | |
| SCHEMBL1761063 | 0.75 | CA12 (0.50) | SLC6A9AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| EP-1841727-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-10 | — | — | EP | disclosed |
| EP-1838663-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | SLC6A9 911/4885SCN8A 380/4885SCN10A 259/4885 |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885SCN8A 2404/4885SCN10A 1241/4885 |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | SLC6A9 911/4885SCN8A 380/4885SCN10A 259/4885 |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | SLC6A7, SLC6A1, SLC6A4 | SLC6A9 27/4885SCN8A 439/4885SCN10A 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.